A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Exclusion Criteria

• •Prior therapy with a RAS, MEK, or ERK inhibitor. Depending on which treatment arm the patient is assigned, other therapies could also be prohibitive.
• •Anti-cancer therapy ≤ 21 days or 4 half-lives prior to first dose of study drug, whichever is shorter.
• •Palliative radiation ≤ 7 days prior to first dose of study drug.
• •Symptomatic brain metastasis or leptomeningeal disease.
• •Gastrointestinal conditions that may affect absorption of oral medications
• •Active infection requiring systemic therapy, or a known history of HIV infection, hepatitis B virus, or hepatitis C virus.
• •History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first study drug dose.
• •Active, clinically significant interstitial lung disease or pneumonitis.
• •Impaired cardiovascular function or clinically significant cardiovascular disease.
• •History of thromboembolic or cerebrovascular events ≤ 6 months prior to first dose.
• •Major surgery within 28 days of enrollment, or anticipation of major surgery during study treatment.
• •Known intolerance or contraindication to encorafenib, cetuximab, or palbociclib.
• •Pregnant or breastfeeding women.
• •Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study.